A rapid and sensitive LC–MS/MS assay for the determination of berbamine in rat plasma with application to preclinical pharmacokinetic study

Liu, Qingwang; Wang, Junsong; Yang, Lei; Jia, Yuanwei; Kong, Ling–Yi

doi:10.1016/j.jchromb.2013.04.007

Cited by 10 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, BBM has shown its potent antitumor activity in different types of cancer including metastatic cancer with reduced toxicity 17, 18, 30, 31 . Though BBM is a potent drug but its half-life in blood plasma is very short, owing to its quick renal clearance 32 . In this context, nanotechnology based drug delivery vehicles are regarded as an emerging approach in cancer therapy as they are able to overcome the above problem 19, 33, 34 .…”

Section: Discussionmentioning

confidence: 99%

Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo

Parhi

Suklabaidya

Sahoo

2017

Sci Rep

View full text Add to dashboard Cite

Research on metastasis is gaining momentum for effective cancer management. Berbamine (BBM) has the potency to act as a therapeutic in multiple cancers and cancer metastasis. However, the major limitation of the compound includes poor bioavailability at the tumor site due to short plasma half-life. Here, our major objective involved development of lipid based nanoparticles (NPs) loaded with BBM with an aim to circumvent the above problem. Moreover its, therapeutic potentiality was evaluated through various in vitro cellular studies and in vivo melanoma primary and experimental lung metastatic tumor model in C57BL/6 mice. Results of different cellular experiments demonstrated enhanced therapeutic efficacy of BBM-NPs in inhibiting metastasis, cell proliferation and growth as compared to native BBM in highly metastatic cancer cell lines. Further, in vivo results demonstrated suppression of primary B16F10 melanoma tumor growth in C57BL/6 mice model treated with BBM-NPs than that of native BBM. Importantly, a moderately cytotoxic dose of BBM-NPs was able to significantly suppress the incidence of B16F10 cells lung metastasis in vivo. Results indicated development of an effective approach for aggressive metastatic cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo

Parhi

Suklabaidya

Sahoo

2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The pharmacokinetic parameters of the three dosages calculated using noncompartmental analysis were shown in Table 3. In this study, it can be seen that the concentration of ailanthone in rat plasma after intravenous administration was relatively high although the dosages were lower than some other PK researches [19][20][21], which might be due to the good solubility of ailanthone. The t 1/2 were 105.5 ± 13.6, 113.3 ± 39.6 and 95.8 ± 23.9 min after administration of 0.5, 1.0, and 1.5 mg/kg ailanthone, respectively, which means that ailanthone is eliminated fast in rats.…”

Section: Pharmacokinetic Studymentioning

confidence: 65%

Development of a validated LC–MS/MS method for the determination of ailanthone in rat plasma with application to pharmacokinetic study

Chen

Qin

et al. 2015

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

“…All of them have been classified into two categories based on the number of analytes. Forty-nine publications involved analyzing one drug (n = 1) and the remaining 23 involved analyzing multiple drugs/metabolites (n ≥ 2) are summarized in Table 1 [4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52] and Table 2 [53,54,55,56,57,58,59,60,61,62,<...>…”

Section: Resultsmentioning

confidence: 99%

A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs

et al. 2018

View full text Add to dashboard Cite

In the last decade, the tremendous improvement in the sensitivity and also affordability of liquid chromatography-tandem mass spectrometry (LC-MS/MS) has revolutionized its application in pharmaceutical analysis, resulting in widespread employment of LC-MS/MS in determining pharmaceutical compounds, including anticancer drugs in pharmaceutical research and also industries. Currently, LC-MS/MS has been widely used to quantify small molecule oncology drugs in various biological matrices to support preclinical and clinical pharmacokinetic studies in R&D of oncology drugs. This mini-review article will describe the state-of-the-art LC-MS/MS and its application in rapid quantification of small molecule anticancer drugs. In addition, efforts have also been made in this review to address several key aspects in the development of rapid LC-MS/MS methods, including sample preparation, chromatographic separation, and matrix effect evaluation.

show abstract

A rapid and sensitive LC–MS/MS assay for the determination of berbamine in rat plasma with application to preclinical pharmacokinetic study

Cited by 10 publications

References 23 publications

Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo

Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo

Development of a validated LC–MS/MS method for the determination of ailanthone in rat plasma with application to pharmacokinetic study

A Review on Liquid Chromatography-Tandem Mass Spectrometry Methods for Rapid Quantification of Oncology Drugs

Contact Info

Product

Resources

About